KNSA Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa

Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit .

ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ®



Kiniksa Investor and Media Contact

Rachel Frank

(339) 970-9437



 



EN
23/11/2022

Underlying

KNSAKiniksa Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kiniksa Pharmaceuticals

 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care...

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical compan...

February 25, 2026 1 EN
Wedbush Research
  • Wedbush Research
VMW VMWARE INC. CLASS A
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
FB FACEBOOK INC. CLASS A
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
AXTI AXT INC.
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
NFLX NETFLIX INC.
OSTK OVERSTOCK.COM INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZS ZSCALER INC.
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
BEAM INC.
LRMR BEAM THERAPEUTICS
VRDN LARIMAR THERAPEUTICS INC
PLTK VIRIDIAN THERAPEUTICS INC
DAWN PLAYTIKA HOLDING
XMTR DAY ONE BIOPHARMACEUTICALS INC
STX XOMETRY
GLUE INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
S MONTE ROSA THERAPEUTICS INC
GETY GLOBALFOUNDRIES INC
SENTINELONE INC
GETTY IMAGES HOLDINGS INC
02/25/26 February 25, 2026 1 EN
 PRESS RELEASE
Free
KNSA Kiniksa Pharmac...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution – ARCALYST® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively –– ARCALYST 2026 net product revenue expected to be $900 - $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by the end of 2026 –– Cash balance increased by $170.4 million in 2025 to $414.1 million –      – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. ...

February 24, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
KNSA KINIKSA PHARMACEUTICALS
02/24/26 February 24, 2026 1 EN
Wedbush Research
  • Wedbush Research
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MNKD MANNKIND CORP.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
NTLA INTELLIA THERAPEUTICS INC.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
RVMD INC.
OCUP REVOLUTION MEDICINES
DAWN OCUPHIRE PHARMA INC
STX DAY ONE BIOPHARMACEUTICALS INC
GLUE SEAGATE TECHNOLOGY HLDGS PLC
GFS MONTE ROSA THERAPEUTICS INC
MLTX GLOBALFOUNDRIES INC
EWTX MOONLAKE IMMUNOTHERAPEUTICS
QBTS EDGEWISE THERAPEUTICS INC
IONQ D-WAVE QUANTUM INC.
DBD IONQ INC
BCAX DIEBOLD NIXDORF INCORPORATED
BICARA THERAPEUTICS INC.
02/23/26 February 23, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch